Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 23 - Neuropsychiatric aspects of the on/off phenomenon

from Section 5 - Other issues

Related content

Powered by UNSILO

References

1. GoetzCG, PoeweW, RascolO, SampaioC.Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523–39.
2. AgidY, OlanowC, MizunoY.Levodopa: why the controversy?Lancet 2002; 360: 575.
3. MiyasakiJM, MartinW, SuchowerskyO, WeinerWJ, LangAE.Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11–17.
4. FoxSH, LangAE.Levodopa-related motor complications: phenomenology. Mov Disord 2008; 23 (Suppl 3): S509–14.
5. AhlskogJE, MuenterMD.Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448–58.
6. SchragA, QuinnN.Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297–305.
7. RileyDE, LangAE.The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459–64.
8. WitjasT, KaphanE, AzulayJP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
9. StacyM, BowronA, GuttmanM, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20: 726–33.
10. LeesAJ.The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989; 52 (suppl): 29–37.
11. HillenME, SageJI.Motor fluctuations in patients with Parkinson's disease. Neurology 1996; 47: 1180–3.
12. GunalDI, NurichalichiK, TuncerN, BekirogluN, AktanS.The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 2002; 29: 61–4.
13. BayulkemK, LopezG.Nonmotor fluctuations in Parkinson's disease: clinical spectrum and classification. J Neurol Sci 2010; 289: 89–92.
14. QuinnNP.Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51 (Suppl 2): 25–29.
15. SchragA.Psychiatric aspects of Parkinson's disease–an update. J Neurol 2004; 251: 795–804.
16. ChaudhuriKR, SchapiraAH.Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–74.
17. OlanowCW, ObesoJA, StocchiF.Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677–87.
18. NuttJG.Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008; 23 (Suppl 3): S580–4.
19. WeintraubD, BurnDJ.Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022–1031.
20. RichardIH, JustusAW, KurlanR.Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 35–41.
21. KulisevskyJ, Pascual-SedanoB, BarbanojM, et al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007; 22: 62–7.
22. MaricleRA, NuttGJ, ValentineRJ, CarterJH.Dose–response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo controlled study. Neurology 1995; 45: 1757–60.
23. VoonV, FernagutPO, WickensJ, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140–9.
24. AarslandD, UweE, RektorovaI.Cognitive and psychiatric disturbances in Parkinson's disease. Aging Health 2011; 7: 123–42.
25. MarshL, McDonaldWM, CummingsJ, RavinaB.Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148–58.
26. JuddMM, RapaportM, PaulusMB.Subsyndromal symptomatic depression: a new mood disorder?J Clin Psychiatry 1994; 55 (suppl): 18–28.
27. MenzaMA, SageJ, MarshallE, CodyR, DuvoisinR.Mood changes and “on–off” phenomena in Parkinson's disease. Mov Disord 1990; 5: 148–51.
28. GiovannoniG, O'SullivanJD, TurnerK, MansonAJ, LeesAJ.Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.
29. LawrenceAD, EvansAH, LeesAJ.Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?Lancet Neurol 2003; 2: 595–604.
30. PontoneGM, WilliamsJR, AndersonKE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24: 1333–8.
31. FunkiewiezA, ArdoinC, CaputoE, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834–9.
32. ThoboisS, ArdouinC, LhomméeE, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.
33. SageJI.Fluctuations of non-motor symptoms. In FactorSA and WeinerWJ, eds., Parkinson's Disease: Diagnosis and Clinical Management. New York, NY: Demos; 2002. pp. 455–63.
34. RaudinoF.Nonmotor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312–15.
35. AarslandD, BrønnickK, Williams-GrayC, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.
36. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707.
37. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
38. ButerTC, van den HoutA, MatthewsFE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017–1022.
39. AarslandD, BrønnickK, LarsenJP, TysnesOB, AlvesG.Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.
40. MegaMS, CummingsJL.Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6: 358–70.
41. JellingerKA.The pathology of Parkinson's disease. Adv Neurol 2001; 86: 55–72.
42. PillonB, DuboisB, CusimanoG, et al. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?J Neurol Neurosurg Psychiatry 1989; 52: 201–6.
43. RektorovaI, SrovnalovaH, KubikovaR, PrasekJ.Striatal dopamine transporter imaging correlates with depressive symptoms and Tower of London task performance in Parkinson's disease. Mov Disord 2008; 23: 1580–7.
44. KoertsJ, LeendersKL, KoningM, PortmanAT, van BeilenM.Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 2007; 25: 3132–6.
45. KulisevskyJ, García-SánchezC, BerthierML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15: 613–26.
46. CoolsR.Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1–23.
47. NieoullonA.Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53–83.
48. RektorovaI.Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease. Neurodegener Dis 2010; 7: 206–9.
49. BrownRD, MarsdenCD, QuinnN, WykeMA.Alterations in cognitive performance and affect arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47: 454–65.
50. GirottiE, CarellaF, GrassiMP, et al. Motor and cognitive performances of Parkinsonian patients in the “on” and “off” phases of the disease. J Neurol Neurosurg Psychiatry 1986; 49: 657–60.
51. MohrE, FabbriniG, WilliamsJ, et al. Dopamine and memory function in Parkinson's disease. Mov Disord 1989; 4: 113–20.
52. GothamAM, BrownRG, MarsdenCD.“Frontal” cognitive function in patients with Parkinson's disease “on” and “off” levodopa. Brain 1988; 11: 299–321.
53. PoeweW, BergerW, BenkeT, ScheolskyL.High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991; 29: 670–3.
54. DelisD, DirenfeldL, AlexanderMP, KaplanE.Cognitive fluctuations associated with on–off phenomenon in Parkinson's disease. Neurology 1982; 32: 1049–52.
55. Pascual-SedanoB, KulisevskyJ, BarbanojM, et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 2008; 14: 832–41.
56. StacyM.The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm 2010; 117: 837–46.
57. StacyM, HauserR, OertelW, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29: 312–21.
58. StacyMA, MurphyJM, GreeleyDR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14: 205–12.
59. BarešM, RektorováI, JechR, et al. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?J Neural Transm 2012; 119: 373–80.
60. RektorovaI, RektorI, BaresM, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399–406.
61. LemkeMR, BrechtHM, KoesterJ, ReichmannH.Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248: 266–70.
62. AntoniniA, TolosaE, MizunoY, YamamotoM, PoeweWH.A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929–37.
63. HorstinkM, TolosaE, BonuccelliU, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186–202.
64. HorowskiR, JahnichenS, PertzH.Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 2004; 19: 1523–4.
65. RůzickaE, StreitováH, JechR, et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Transm 2000; 107: 1297–306.
66. DeweyRB, HuttonJT, LeWittPA, FactorSA.A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385–92.
67. KatzenschlagerR, HughesA, EvansA, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151–7.
68. AntoniniA, IsaiasIU, CanesiM, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145–9.
69. StocchiF, VaccaL, RuggieriS, OlanowCW.Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905–10.
70. BenabidAL, ChabardesS, MitrofanisJ, PollakP.Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009; 8: 67–81.
71. TemelY, BloklandA, SteinbuschHWM, Visser-VandewalleV.The functional role of the subthalamic nucleus in cognitive and limbic circuits. Progr Neurobiol 2005; 76: 393–413.
72. OkunMS, FernandezHH, WuSS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65: 586–95.
73. WittK, PulkowskiU, HerzogJ, et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 2004; 61: 697–700.
74. TemelY, KesselsA, TanS, et al. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2006; 12: 265–72.
75. VoonV, KubuC, KrackP, HouetoJL, TrösterAI.Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 (Suppl 14): S305–27.
76. FunkiewiezA, ArdouinC, KrackP, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–30.
77. LimSY, O'SullivanSS, KotschetK, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–52.
78. HerzogJ, ReiffJ, KrackP, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov Disord 2003; 18: 1382–4.
79. CzerneckiV, PillonB, HouetoJL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?J Neurol Neurosurg Psychiatry 2005; 76: 775–9.
80. KrackP, BatirA, Van BlercomN, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925–34.
81. StruttAM, SimpsonR, JankovicJ, YorkMK.Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 2012; 19: 121–7.
82. WitjasT, KaphanE, RégisJ, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007; 22: 1729–34.
83. PillonB, ArdouinC, DamierP, et al. Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson's disease. Neurology 2000; 55: 411–18.
84. JahanshahiM, ArdouinC, BrownRG, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2000; 123: 1142–54.
85. SmedingHM, SpeelmanJD, Koning-HaanstraM, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66: 1830–6.
86. KrackP, PollakP, LimousinP, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121: 451–7.
87. HouetoJL, MesnageV, MalletL, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701–7.